IceCure Reports Strong 5-Year Kidney Cancer Cryoablation Results, Boosting ProSense® Commercial Outlook
Summary
IceCure Medical announced positive 5-year top-line results from its ICESECRET study for kidney cancer cryoablation, showing high recurrence-free rates and supporting broader commercial adoption of its ProSense® system.
Key Events
-
Positive 5-Year Kidney Cancer Study Results
The ICESECRET clinical trial reported an 89.4% recurrence-free rate for tumors ≤3 cm and 83.9% for the general study population at a median 4-year follow-up.
-
Supports Broader Commercial Adoption
The positive long-term data is expected to drive increased commercial use of the ProSense® system for small renal masses in markets where it is already approved.
-
Full Data Presentation Scheduled
More detailed results from the study will be presented at the European Conference on Interventional Oncology (ECIO) from April 26-30, 2026.
Analysis
This filing provides crucial positive news for IceCure Medical, especially following its recent "going concern" disclosure. The 5-year top-line results from the ICESECRET study demonstrate strong efficacy and durability for ProSense® in treating small renal masses, with high recurrence-free rates. This long-term data is vital for driving physician adoption and commercial sales in markets where ProSense® is already approved for kidney cancer, potentially improving the company's revenue outlook and addressing its financial challenges. The full data presentation at ECIO 2026 will be a key event to watch for further details.
At the time of this filing, ICCM was trading at $0.64 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $41.8M. The 52-week trading range was $0.54 to $1.40. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.